Announcements Trials
Browse Landscape

Status

Recruiting 1No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

zanubrutinib 1talquetamab 1sugemalimab 1revumenib 1loncastuximab tesirine 1fludarabine phosphate 1denileukin diftitox 1Whole-Body Irradiation 1Tacrolimus 1Panobinostat 1Mycophenolic Acid 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × Recurrence × loncastuximab tesirine × Clear all
NCT04705454 2021-05-12

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics S.A.

No longer available
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡